Skip to main content

Stephen Greene

Associate Professor of Medicine
Medicine, Cardiology

Overview


I am a cardiologist with a clinical and research interest in heart failure. I take care of patients with various types of heart failure, including patients who are best treated with medications and patients who receive advanced therapies like heart transplantation and mechanical assist devices. I became a heart failure cardiologist to help patients manage their heart conditions and best achieve their goals for their health. I am strongly committed to helping patients thoroughly understand their medical conditions and helping them make informed medical decisions aligned with their preferences.

My research interests are focused on strategies and therapies to improve outcomes and quality of life for patients with heart failure. This involves research through clinical trials and through examining data from real-world clinical practice. Below, you will find my specific research interests:

  • Use and dosing of evidence-based heart failure medications
  • Management of worsening heart failure outside the hospital
  • Novel pharmacological and non-pharmacological approaches to heart failure
  • Improving outcomes following a hospitalization for heart failure
  • Surrogate and nonfatal endpoints in heart failure clinical trials
  • Clinical trial design and operations
  • Improving site-based heart failure research

Current Appointments & Affiliations


Associate Professor of Medicine · 2024 - Present Medicine, Cardiology, Medicine
Member in the Duke Clinical Research Institute · 2020 - Present Duke Clinical Research Institute, Institutes and Centers

In the News


Published May 27, 2025
New Dosing Can Reduce Risk of Heart Failure

View All News

Recent Publications


A Pragmatic Trial Evaluating the Impact of the Anumana Clinical Decision Support Tool for Guideline-Directed Management of Heart Failure (ACT-HF): Clinical trial design and methods.

Conference Am Heart J Plus · January 2026 BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) is progressive and pervasive. Guidelines provide evidence-based recommendations to manage HFrEF, yet adherence to Guideline Directed Medical Therapy (GDMT) is low. An opportunity exists to im ... Full text Link to item Cite

Trends and Projections in Hypertension-Related Mortality in the United States: A 1979-2050 CDC WONDER Analysis.

Journal Article High Blood Press Cardiovasc Prev · December 24, 2025 INTRODUCTION: Hypertension remains a leading modifiable risk factor for cardiovascular morbidity and mortality in the United States. Despite advances in detection and treatment, the burden of hypertension-related deaths continues to challenge public health ... Full text Link to item Cite

Victoria and Victor: event-driven lessons for integrating vericiguat into practice and reducing residual risk in HFrEF.

Journal Article Heart Fail Rev · December 11, 2025 Chronic heart failure with reduced ejection fraction (HFrEF) is a progressive syndrome associated with substantial residual morbidity and mortality despite contemporary guideline-directed medical therapy (GDMT) - angiotensin-converting enzyme inhibitors (A ... Full text Link to item Cite
View All Publications

Recent Grants


REFOCUS-HTN US

Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2025 - 2027

Post-Hoc Analysis of the TRANSFORM Trial

ResearchPrincipal Investigator · Awarded by University of Texas - Southwestern · 2025 - 2026

View All Grants

Education, Training & Certifications


Northwestern University, Feinberg School of Medicine · 2012 M.D.